Article Details

Genetech's glofitamab demonstrates durable complete response in large B-cell lymphoma

Retrieved on: 2022-05-27 19:57:13

Tags for this article:

Click the tags to see associated articles and topics

Genetech's glofitamab demonstrates durable complete response in large B-cell lymphoma. View article details on hiswai:

Excerpt

Roche (OTCQX:RHHBY), the parent company of Genentech, recently won European Commission approval of Polivy (polatuzumab vedotin) for diffuse large ...

Article found on: seekingalpha.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up